{"entity":{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","aka":[],"tldr":"Eryaspase, an enzyme carried inside red blood cells, did not lengthen survival when added to second-line chemotherapy for pancreatic cancer.","summary":"TRYbeCA-1 randomised patients with metastatic pancreatic adenocarcinoma progressing after first-line treatment to eryaspase plus gemcitabine and nab-paclitaxel or irinotecan-based chemotherapy, or chemotherapy alone. The primary endpoint of overall survival was not met when the trial reported in 2021.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03665441","url":"https://clinicaltrials.gov/study/NCT03665441"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["eryaspase","gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03665441","phase":"3","setting":"Second-line metastatic pancreatic adenocarcinoma: eryaspase with chemotherapy versus chemotherapy alone","sponsor":"Erytech Pharma","result":"Primary overall survival endpoint not met.","yearReported":2021,"outcomes":[]},"route":"/trials/trybeca-1/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/"},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}]}}